Aiming to revolutionize anticancer drug discovery by moving beyond traditional animal models, Mobius Bio has successfully raised $30.0M. The biotech firm leverages a unique, clinically validated platform that integrates frontier AI with a proprietary wet lab, allowing it to interrogate disease mechanisms directly in live human tissue samples.
This approach is designed to uncover novel molecules rooted in human biology, with the ultimate goal of delivering transformative treatments for patients with high unmet medical needs.


















